✦ LIBER ✦
7107 A randomized, prospective, Phase 2 study, with Sorafenib (So) and Interleukin-2 (IL-2) versus So alone as first line treatment in advanced Renal Cell Cancer (RCC): ROSORC Trial
✍ Scribed by Procopio, G.; Verzoni, E.; Bracarda, S.; Ricci, S.; Miceli, R.; Bertolini, A.; Porta, C.; Ridolfi, R.; Zilembo, N.; Bajetta, E.
- Book ID
- 123556970
- Publisher
- Elsevier Science
- Year
- 2009
- Tongue
- English
- Weight
- 49 KB
- Volume
- 7
- Category
- Article
- ISSN
- 1359-6349
No coin nor oath required. For personal study only.